Advertisement

Rheumatology International

, Volume 39, Issue 1, pp 73–81 | Cite as

Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?

  • Gamze KilicEmail author
  • Erkan Kilic
  • Kemal Nas
  • Ayhan Kamanlı
  • İbrahim Tekeoglu
Observational Research
  • 80 Downloads

Abstract

The aim of this study was to investigate residual symptoms or disease burden among patients with psoriatic arthritis (PsA) in remission or low disease activity (LDA) according to different outcome measures. A total of 126 patients with PsA were included and the following variables were assessed: Tender joint count (TJC), swollen joint count (SJC), patient’s global assessment, physician’s global assessment, pain, extra-articular manifestations, Psoriasis Area and Severity Index, Health Assessment Questionnaire, fatigue, Short Form-36, psoriatic quality of life, Hospital Anxiety and Depression Scale and C-reactive protein (CRP). Disease activity was measured using three different outcome measures including minimal disease activity (MDA), disease activity score for 28 joints (DAS28-CRP) and disease activity in psoriatic arthritis (DAPSA). The number (%) of patients who achieved remission or LDA was 9(14.1), 34(27.0) and 67(53.2) according to MDA, DAPSA and DAS28-CRP criteria, respectively, under usual care. SJC > 1 was seen in 3(8.8%) and 13(19.4%) of patients in remission or LDA as defined by the DAPSA and DAS28-CRP respectively. TJC > 1 was found at least 32.4% of patients with PsA in remission or LDA by any definition. 22.2–49.3% of patients with PsA in remission or LDA still suffered from clinically important fatigue. No patients in MDA had a substantial functional impairment while 2.9–19.4% of patients fulfilling remission or LDA according to the DAPSA and DAS28-CRP experienced functional disability. At least 22.2% of patients with PsA in remission or LDA by any description had higher risk for depression, and at least 11.1% for anxiety. Despite patients with PsA in remission or LDA by various definition, they may continue to experience pain, tender or swollen joints, fatigue, physiologic distress as well as functional impairment suggesting that there is a significant unmet need with regard to definition of remission or LDA in PsA.

Keywords

Disease activity Disease burden Minimal disease activity Psoriatic arthritis Remission 

Notes

Author contributions

GK is a corresponder author who has made substantial contribution to conception, design, interpretation of data and publication process. She has also participated in the review, drafting, and final approval of the manuscript. EK has made substantial contributions to the design, analysis and interpretation of data. He has drafted the manuscript for important intellectual content and also participated in final approval of the manuscript. KN has made substantial contributions to acquisition of data and drafting the article. He has approved the final version of the manuscript. AK has made substantial contributions to acquisition of data, drafting the article and approved the final version of the manuscript. İT has made substantial contributions to acquisition of data, revised article critically for important intellectual content and approved the final version of the manuscript.

Compliance with ethical standards

Conflict of interest

We have no conflicts of interest with respect to the authorship and/or publication of this article.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All subjects in this study have been informed for the study protocol and written informed consents have been obtained.

References

  1. 1.
    Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(suppl 2):14–17.  https://doi.org/10.1136/ard.2004.032482 Google Scholar
  2. 2.
    Nas K, Karkucak M, Durmus B, Karatay S, Capkin E, Kaya A, Ucmak D, Akar ZA, Cevik R, Kilic E, Kilic G, Ozgocmen S (2015) Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis. Int J Rheum Dis 18:873–879.  https://doi.org/10.1111/1756-185X.12580 CrossRefGoogle Scholar
  3. 3.
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269.  https://doi.org/10.1016/S0140-6736(04)16676-2 CrossRefGoogle Scholar
  4. 4.
    Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Compan V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA (2016) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 75:16–22.  https://doi.org/10.1136/annrheumdis-2015-207526 CrossRefGoogle Scholar
  5. 5.
    Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL, Meads DM, Emery P, Conaghan PG, Helliwell PS (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386:2489–2498.  https://doi.org/10.1016/S0140-6736(15)00347-5 CrossRefGoogle Scholar
  6. 6.
    Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77:3–17.  https://doi.org/10.1136/annrheumdis-2017-211734 CrossRefGoogle Scholar
  7. 7.
    Nas K, Kilic E, Cevik R, Bodur H, Ataman S, Ayhan F, Akgul O, Akinci A, Altay Z, Capkin E, Dagli AZ, Duruoz T, Gurer G, Gogus F, Garip Y, Kacar C, Kamanli A, Kaptanoglu E, Kaya T, Kocabas H, Ozdemirel EA, Ozel S, Sezer I, Sunar I, Yilmaz G (2018) Management of psoriatic arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions. Arch Rheum 33:108–127.  https://doi.org/10.5606/ArchRheumatol.2018.6946 CrossRefGoogle Scholar
  8. 8.
    Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499–510.  https://doi.org/10.1136/annrheumdis-2015-208337 CrossRefGoogle Scholar
  9. 9.
    Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O’Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68:1060–1071.  https://doi.org/10.1002/art.39573 Google Scholar
  10. 10.
    Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O’Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM (2017) Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT Working Group. J Rheumatol 44:697–700.  https://doi.org/10.3899/jrheum.170150 CrossRefGoogle Scholar
  11. 11.
    Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, Van Riel PL (2006) Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 65:1373–1378.  https://doi.org/10.1136/ard.2006.051706 CrossRefGoogle Scholar
  12. 12.
    Gladman DD, Tom BD, Mease PJ, Farewell VT (2010) Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol 37:1892–1897.  https://doi.org/10.3899/jrheum.091172 CrossRefGoogle Scholar
  13. 13.
    Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS (2000) Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology 39:148–155CrossRefGoogle Scholar
  14. 14.
    Coates LC, Helliwell PS (2016) Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 43:371–375.  https://doi.org/10.3899/jrheum.150826 CrossRefGoogle Scholar
  15. 15.
    Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69:48–53.  https://doi.org/10.1136/ard.2008.102053 CrossRefGoogle Scholar
  16. 16.
    Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72:986–991.  https://doi.org/10.1136/annrheumdis-2012-201341 CrossRefGoogle Scholar
  17. 17.
    Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S (2016) Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken) 68:267–274.  https://doi.org/10.1002/acr.22576 CrossRefGoogle Scholar
  18. 18.
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Group CS (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673.  https://doi.org/10.1002/art.21972 CrossRefGoogle Scholar
  19. 19.
    Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ (1997) Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 24:511–517Google Scholar
  20. 20.
    McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ (2004) Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 63:162–169CrossRefGoogle Scholar
  21. 21.
    Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145CrossRefGoogle Scholar
  22. 22.
    Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370CrossRefGoogle Scholar
  23. 23.
    Fredriksson T, Pettersson U (1978) Severe psoriasis–oral therapy with a new retinoid. Dermatologica 157:238–244CrossRefGoogle Scholar
  24. 24.
    Coates LC, Helliwell PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62:965–969.  https://doi.org/10.1002/acr.20155 CrossRefGoogle Scholar
  25. 25.
    Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS (2010) Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 69:1441–1447.  https://doi.org/10.1136/ard.2009.122259 CrossRefGoogle Scholar
  26. 26.
    Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48CrossRefGoogle Scholar
  27. 27.
    Gladman DD, Mease PJ, Healy P, Helliwell PS, Fitzgerald O, Cauli A, Lubrano E, Krueger GG, van der Heijde D, Veale DJ, Kavanaugh A, Nash P, Ritchlin C, Taylor W, Strand V (2007) Outcome measures in psoriatic arthritis. J Rheumatol 34:1159–1166Google Scholar
  28. 28.
    Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75:811–818.  https://doi.org/10.1136/annrheumdis-2015-207507 CrossRefGoogle Scholar
  29. 29.
    Mease PJ, Coates LC (2018) Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum 47:786–796.  https://doi.org/10.1016/j.semarthrit.2017.10.021 CrossRefGoogle Scholar
  30. 30.
    Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS (2018) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol 70:345–355.  https://doi.org/10.1002/art.40391 CrossRefGoogle Scholar
  31. 31.
    Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, Heiberg T, Helliwell PS, Kalyoncu U, Kvien TK, Kiltz U, Niedermayer D, Otsa K, Scrivo R, Smolen J, Stamm TA, Veale DJ, de Vlam K, de Wit M, Gossec L (2017) Determinants of patient–physician discordance in global assessment in psoriatic arthritis: a multicenter European Study. Arthritis Care Res (Hoboken) 69:1606–1611.  https://doi.org/10.1002/acr.23172 CrossRefGoogle Scholar
  32. 32.
    van Mens LJJ, Turina MC, van de Sande MGH, Nurmohamed MT, van Kuijk AWR, Baeten DLP (2018) Residual disease activity in psoriatic arthritis: discordance between the rheumatologist’s opinion and minimal disease activity measurement. Rheumatology (Oxford) 57:283–290.  https://doi.org/10.1093/rheumatology/kex183 CrossRefGoogle Scholar
  33. 33.
    Husted JA, Gladman DD, Farewell VT, Cook RJ (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 45:151–158.  https://doi.org/10.1002/1529-0131(200104)45:2%3C151::AID-ANR168%3E3.0.CO;2-T CrossRefGoogle Scholar
  34. 34.
    Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD (2009) Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis 68:1553–1558.  https://doi.org/10.1136/ard.2008.098202 CrossRefGoogle Scholar
  35. 35.
    Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47:351–360.  https://doi.org/10.1016/j.semarthrit.2017.05.010 CrossRefGoogle Scholar
  36. 36.
    Freire M, Rodriguez J, Moller I, Valcarcel A, Tornero C, Diaz G, Armendariz Y, Paredes S (2011) Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Reumatol Clin 7:20–26.  https://doi.org/10.1016/j.reuma.2010.03.003 CrossRefGoogle Scholar
  37. 37.
    van Mens LJJ, van de Sande MGH, Fluri IA, Atiqi S, van Kuijk AWR, Baeten DLP (2017) Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice. Arthritis Res Ther 19:226.  https://doi.org/10.1186/s13075-017-1424-8 CrossRefGoogle Scholar
  38. 38.
    Marin J, Acosta Felquer ML, Ferreyra Garrot L, Ruta S, Rosa J, Soriano ER (2016) Patients with psoriatic arthritis fulfilling the minimal disease activity criteria do not have swollen and tender joints, but have active skin. J Rheumatol 43:907–910.  https://doi.org/10.3899/jrheum.151101 CrossRefGoogle Scholar
  39. 39.
    van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC (2018) Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis 77:251–257.  https://doi.org/10.1136/annrheumdis-2017-211998 CrossRefGoogle Scholar
  40. 40.
    Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 42:1460–1468.  https://doi.org/10.1093/rheumatology/keg384 CrossRefGoogle Scholar
  41. 41.
    Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68:702–709.  https://doi.org/10.1136/ard.2008.092767 CrossRefGoogle Scholar
  42. 42.
    Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976–986.  https://doi.org/10.1002/art.24403 CrossRefGoogle Scholar
  43. 43.
    Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD (2004) Treatment of refractory psoriatic arthritis with infliximab: a 12-month observational study of 16 patients. Ann Rheum Dis 63:156–161CrossRefGoogle Scholar
  44. 44.
    Haddad A, Thavaneswaran A, Ruiz-Arruza I, Pellett F, Chandran V, Cook RJ, Gladman DD (2015) Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res (Hoboken) 67:842–847.  https://doi.org/10.1002/acr.22529 CrossRefGoogle Scholar
  45. 45.
    Overman CL, Kool MB, Da Silva JA, Geenen R (2016) The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol 35:409–415.  https://doi.org/10.1007/s10067-015-3035-6 CrossRefGoogle Scholar
  46. 46.
    Sokoll KB, Helliwell PS (2001) Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 28:1842–1846Google Scholar
  47. 47.
    Wervers K, Vis M, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael J, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Luime JJ, The behalf of C (2018) Burden of psoriatic arthritis in different definitions of disease activity: comparing minimal disease activity and disease activity index for psoriatic arthritis. Arthritis Care Res (Hoboken).  https://doi.org/10.1002/acr.23571 Google Scholar
  48. 48.
    McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, Gladman DD (2014) Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 41:887–896.  https://doi.org/10.3899/jrheum.130797 CrossRefGoogle Scholar
  49. 49.
    Kavanaugh A, Fransen J (2006) Defining remission in psoriatic arthritis. Clin Exp Rheumatol 24(6 Suppl 43):S–S83Google Scholar
  50. 50.
    Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O (2016) The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 43:1749–1754.  https://doi.org/10.3899/jrheum.151491 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Physical Medicine and RehabilitationAfyon Kocatepe University Faculty of MedicineAfyonkarahisarTurkey
  2. 2.Afyonkarahisar State HospitalRhematology ClinicAfyonkarahisarTurkey
  3. 3.Division of Rheumatology and Immunology, Department of Physical Medicine and RehabilitationSakarya University Faculty of MedicineSakaryaTurkey

Personalised recommendations